Skip to main content
Hyper Corporation Inc. logo

Hyper Corporation Inc. — Investor Relations & Filings

Ticker · 065650 ISIN · KR7065650004 KO Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 391 across all filing types
Latest filing 2020-12-09 M&A Activity
Country KR South Korea
Listing KO 065650

About Hyper Corporation Inc.

https://hyper-corp.com/

Hyper Corporation Inc. is a company transitioning from a clinical-stage biopharmaceutical firm to a new-tech-based platform provider. Its core Bio & Healthcare division develops treatments and diagnostic technologies for neurodegenerative diseases like Alzheimer's, aiming to build a comprehensive digital senior healthcare platform. The company is expanding by integrating AI and blockchain technologies into new sectors. Its IP & Content division focuses on securing intellectual property and innovating content distribution, while its New Tech division develops platforms to connect online and offline services. This strategy fuses its biotechnology expertise with advanced IT to create new business models and services.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(회사합병결정)
M&A Activity Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a corporate merger (회사합병 결정) between Medifron DBT and its subsidiary SJ Core. It details the merger agreement, the rationale (management efficiency), the merger ratio (1:0, as it is a small-scale merger of a 100% owned subsidiary), and the timeline. This falls under the category of M&A activity (mergers and acquisitions).
2020-12-09 Korean
주요사항보고서(회사합병결정)
M&A Activity Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a corporate merger (회사합병 결정) between Medifron DBT and SJ Core. It details the merger method, purpose, financial impact, and legal procedures (such as the small-scale merger process under the Commercial Act). This type of filing is specifically categorized as M&A Activity (TAR) in the provided schema.
2020-12-07 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the suspension of share registration (shareholder register closure) for the purpose of determining shareholders for a small-scale merger. It does not contain the full merger agreement or financial statements, but rather serves as a formal notice of a corporate action. Since it does not fit into specific categories like M&A activity (which would be the full merger document) or dividend notices, and is a standard regulatory disclosure filed with the KRX, it is classified as a general regulatory filing.
2020-12-07 Korean
증권발행결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Securities Issuance Result' (증권 발행결과) announcement regarding the issuance of bonds with warrants (신주인수권부사채). It details the issuance amount, payment date, and method. This falls under the category of capital and financing updates, specifically related to the issuance of debt instruments.
2020-12-04 Korean
전환가액의조정
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price of convertible bonds (CB) for the company Medifron. It details the change in conversion price, the number of convertible shares, and the methodology used for the adjustment based on market price fluctuations. This type of disclosure is a standard corporate action related to capital structure and financing instruments, which falls under the 'Capital/Financing Update' category.
2020-12-01 Korean
주요사항보고서(신주인수권부사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding the issuance of bonds with warrants (신주인수권부사채 발행결정). This document details the terms of the financing, including interest rates, conversion prices, and the use of proceeds. It is a formal regulatory filing detailing a capital structure change and financing activity, which falls under the 'Capital/Financing Update' category.
2020-11-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.